WELCOME

We are pleased to invite you to attend the 1st International Congress on Clinical Research with Biopharmaceutical Products, Clinical Biopharm 2025, which will take place from October 20 to 24, 2025, at the Meliá Internacional Varadero Hotel, Matanzas, Cuba.

It will be a space where clinical specialists, scientists, businessmen, and opinion leaders will exchange their experiences and update their knowledge on clinical research involving innovative therapeutic products. The program will include a broad scientific focus on advances in oncology in the prevention, diagnosis, and treatment of cancer; research into interferons, cytokines, and other biopharmaceuticals; and clinical evaluations in autoimmune, cardiovascular, neurodegenerative, and cerebrovascular diseases, among others.

On this occasion, three symposia will showcase results of scientific and social impact resulting from the clinical development of biopharmaceutical industry products:

Symposium No. 1: Clinical applications of interferons.

• Historical perspective of Cuban clinical trials on interferons (IFNs).
• Present and future of Cuban clinical research on IFNs in Cancer and infectious diseases
• Pediatric use of IFNs.

Symposium No. 2: Advances in Clinical Cancer Research. 1st National Workshop on Clinical Cancer Research with Biopharmaceutical Products.

New targets and challenges in clinical trials with molecular therapeutics and immunotherapy:

• Educational Intervention in Cancer Patients.
• Methodologies for the design and approach to oncological clinical trials.
• Implementing Cancer Prevention and diagnostics into Clinical Practice.
• Advances in Technologies, radiation and imaging in Oncology clinical Trials.
• Clinical Trials with Biopharmaceutical Products in Oncology.
• Regulatory landscape for oncology clinical trials.

Symposium No. 3: Advances in clinical research of biotechnological products for the management of chronic non-communicable diseases.

• Clinical trials of new biotechnology therapies and treatments.
• Regulation and approval of biotechnology products.
• Advances in the diagnosis and monitoring of chronic diseases.
• Impact of biotechnology therapies on public health.
• Collaborations between academia and industry.

The symposium will highlight clinical outcomes and innovative approaches related to: a) cardiac and cerebrovascular diseases; b) chronic lower respiratory tract diseases; c) neurodegenerative disorders (with an emphasis on Alzheimer’s disease and other dementias, Parkinson’s disease, and cerebellar ataxias); d) diabetes; e) nephritis, nephrotic syndrome, and nephrosis; f) chronic liver disease and cirrhosis; g) autoimmune diseases; other chronic non-communicable diseases; and advanced diagnostic techniques for chronic non-communicable diseases.

We look forward to your valuable presence at Cuba’s most famous resort to promote the advancement and development of scientific research in these fields.

We respectfully request the financial collaboration of your entity to enhance the success of this congress:

Organizing Committee